ChiCTR2500102687 版本V1.0 版本创建时间2025/05/19 10:15:24 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500102687 

最近更新日期:

Date of Last Refreshed on:

2025-05-19 10:15:17 

注册时间:

Date of Registration:

2025-05-19 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

干预映射指导下的同伴支持联合团体辅导改善肝癌患者心理痛苦

Public title:

Peer support combined with group counseling under intervention mapping guidance improves psychological distress in liver cancer patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

干预映射指导下的同伴支持联合团体辅导改善肝癌患者心理痛苦

Scientific title:

Peer support combined with group counseling under intervention mapping guidance improves psychological distress in liver cancer patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

何叶 

研究负责人:

何叶 

Applicant:

He Ye 

Study leader:

He Ye 

申请注册联系人电话:

Applicant telephone:

+86 15179166610

研究负责人电话:

Study leader's telephone:

+86 15179166610

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

840282894@qq.com

研究负责人电子邮件:

Study leader's E-mail:

840282894@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江西省南昌市青山湖区北京东路519号

研究负责人通讯地址:

北京东路519号

Applicant address:

No. 519 Beijing East Road, Qingshanhu District, Nanchang City, Jiangxi Province

Study leader's address:

519 Beijing Dong Lu, Nanchang City, Jiangxi Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江西省肿瘤医院

Applicant's institution:

Jiangxi Provincial Cancer Hospital

研究负责人所在单位:

江西省肿瘤医院

Affiliation of the Leader:

Jiangxi Provincial Cancer Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025ky144

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

江西省肿瘤医院医学伦理委员

Name of the ethic committee:

Medical Ethics Committee Member of Jiangxi Cancer Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-03-07 00:00:00

伦理委员会联系人:

陈小丹

Contact Name of the ethic committee:

Chen XiaoDan

伦理委员会联系地址:

北京东路519号

Contact Address of the ethic committee:

519 Beijing Dong Lu, Nanchang City, Jiangxi Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 791 88330236

伦理委员会联系人邮箱:

Contact email of the ethic committee:

459505076@qq.com

研究实施负责(组长)单位:

江西省肿瘤医院

Primary sponsor:

Jiangxi Provincial Cancer Hospital

研究实施负责(组长)单位地址:

北京东路519号

Primary sponsor's address:

519 Beijing Dong Lu, Nanchang City, Jiangxi Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江西省

市(区县):

Country:

China

Province:

Jiangxi

City:

单位(医院):

江西省肿瘤医院

具体地址:

北京东路519号

Institution
hospital:

Jiangxi Provincial Cancer Hospital

Address:

519 Beijing Dong Lu, Nanchang City, Jiangxi Province, China

经费或物资来源:

Source(s) of funding:

None

Target disease:

Liver cancer

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本项目以IM为指导框架,构建以专科护士为主导的多学科心理管理团队,依托省癌症中心、省肝癌诊治中心、省抗癌俱乐部及医院社工部等平台,给予患者从入院到出院需求导向下的同伴支持联合团体辅导,为患者提供全程、全面、全队、全人及全家的”五全”心理管理体系。结果显示项目实施后,肝癌患者心理痛苦程度由中重度下降至轻中度,生活质量得到明显提升。  

Objectives of Study:

This project, guided by the IM framework, constructs a multidisciplinary psychological management team led by specialized nurses, relying on platforms such as the Provincial Cancer Center, the Provincial Liver Cancer Diagnosis and Treatment Center, the Provincial Anti-Cancer Club, and the Hospital Social Work Department, to provide patients with peer support and counseling based on their needs from admission to discharge, offering a "five-whole" psychological management system that covers the entire process, comprehensively, with the whole team the whole person, and the whole family. The results show that after the implementation of the project, the degree of psychological distress of liver cancer patients has decreased from moderate severe to mild to moderate, and their quality of life has been significantly improved.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1、经病理或影像检查确诊为原发性肝癌的初诊患者;
2、年龄18-70岁;
3、意识清楚,能正常交流和阅读者;
4、知晓病情且自愿参加。

Inclusion criteria

1、Patients who were diagnosed with primary liver cancer by pathological or imaging examination for the first time;
2、Ages 18-70 years old;
3、With clear consciousness, who can communicate and read normally;
4、Know the condition and are willing to participate voluntarily.

排除标准:

1、危重症患者;
2、患有精神疾病或认知障碍,无法准确表达自身心理感受;
3、合并其他严重的躯体疾病,如严重心脑血管疾病、肾功能衰竭等;
4、近期(过去1个月内)接受过其他心理干预治疗;

Exclusion criteria:

1、Critically ill patients;
2、Patients with mental illness or cognitive impairment who are unable to accurately express their psychological feelings;
3、Patients with other severe diseases, such as severe cardiovascular and cerebrovascular diseases, renal failure, etc.;
4、Patients who have received other psychological intervention treatment recently (within the past).

研究实施时间:

Study execute time:

From 2025-03-01 00:00:00 To 2026-03-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-06-01 00:00:00 To 2025-12-31 00:00:00  

干预措施:

Interventions:

组别:

实验组

样本量:

50

Group:

Test group

Sample size:

干预措施:

同伴支持联合团体辅导

干预措施代码:

Intervention:

Peer support joint group counseling

Intervention code:

组别:

对照组

样本量:

50

Group:

Control Group

Sample size:

干预措施:

常规护理措施,由责任护士按照护理常规进行入院评估、护理、宣教及出院指导,抗癌俱乐部的志愿者为患者提供1次同伴支持。

干预措施代码:

Intervention:

Routine nursing measures, by the responsible nurse according to nursing routine for admission assessment, nursing, education and discharge guidance,

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江西省 

市(区县):

 

Country:

China 

Province:

Jiangxi 

City:

 

单位(医院):

江西省肿瘤医院 

单位级别:

三级甲等 

Institution
hospital:

Jiangxi Provincial Cancer Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

心理痛苦

指标类型:

主要指标

Outcome:

psychological distress

Type:

Primary indicator

测量时间点:

治疗期间

测量方法:

将患者治疗期间分为:诊断期(入院至治疗前1天)、治疗期(治疗日第1至3天)、出院准备期(治疗日第4天至出院)及出院后随访期。针对这4个时期患者不同需求给予不同干预。

Measure time point of outcome:

During treatment

Measure method:

The patient's treatment period was divided into: the diagnosis period (from admission to the day before treatment), the treatment period (from the first to the day of treatment), the discharge preparation period (from the fourth day of treatment to discharge), and the follow-up period after discharge. Different interventions were given according to the different needs of patients in these four periods.

指标中文名:

生活质量

指标类型:

主要指标

Outcome:

quality of life

Type:

Primary indicator

测量时间点:

治疗期间

测量方法:

欧洲癌症研究和治疗组生活质量问卷-肝细胞癌18

Measure time point of outcome:

During treatment

Measure method:

European Cancer Research and Treatment Group Quality of Life Questionnaire - Hepatocellular Carcinoma 18

指标中文名:

创伤后成长水平

指标类型:

主要指标

Outcome:

Post traumatic growth level

Type:

Primary indicator

测量时间点:

治疗期间

测量方法:

创伤后成长水平量表

Measure time point of outcome:

During treatment

Measure method:

Posttraumatic Growth Scale

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

多学科团队专业人员进行中央随机法

Randomization Procedure (please state who generates the random number sequence and by what method):

A multidisciplinary team of professionals conducts central randomization.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

开放标签

Blinding:

Open-label study

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

邮箱 邮箱号:840282894@qq.com

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

email Email Number: 840282894@qq.com

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

EDC系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC system

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-05-19 10:15:17